IDH1 and acute myeloid leukemia: Whereas Ivosidenib (AG-120) and Enasidenib (AG-221) are FDA-approved for the treatment of relapsed or refractory IDH-mutant AML, trials are ongoing to assess the effectiveness of various IDH inhibitors in the context of solid tumors such as gliomas [145].